Ontada research presented at ISPOR 2026 shows the NCCN Distress Thermometer can predict overall survival in metastatic cancers, but the relationship varies by cancer type.
Ontada finds that EHR-based education boosts NCCN guideline-concordant care for patients with HER2-low metastatic cancer, raising targeted treatment use among providers who took part in the education activities.
In an interview during ASH 2025, Ontada's Ira Zackon, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia treatment, highlighting real-world challenges and emerging therapy strategies.
McKesson's Precision Care Companion initiative enhances biomarker testing and targeted therapies in community oncology, improving patient outcomes and cost efficiency.
McKesson's report highlights key trends in community oncology, emphasizing patient-centered care, precision medicine, and the need for innovative clinical trials.
Leaders from The US Oncology Network and McKesson discuss how technology can enhance precision medicine and improve patient access to cutting-edge cancer treatments.
Systemic barriers beyond just the price of drugs can impact health care costs, emphasizing the need for comprehensive affordability solutions, explained H. John Beardsley, MBA, of CoverMyMeds, and Fauzea Hussain, MPH, of McKesson.
Specialty distributors can help navigate complex health care regulations, ensuring compliance and adapting to changes in the landscape, said Natalie Bedford of McKesson.
Joe DePinto, MBA, of McKesson; Kathi Henson, MBA, of Orsini; and Natalie Bedford of McKesson discuss how Asembia's AXS25 Specialty Summit fosters collaboration among industry leaders, exploring technology trends to enhance specialty pharmacy and patient care delivery.
An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.
The renewal for the ninth straight year includes McKesson's latest measure for resolution of health-related social needs.
Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among Black patients compared with clinical trials.
Leveraging Microsoft’s Azure OpenAI, Ontada streamlines oncology data analysis, reducing processing times by 85% to support clinical decisions and improve patient care for over 3000 oncologists across 30 states, according to Wanmei Ou, PhD, vice president of product, data analytics, and artificial intelligence (AI) at Ontada.
Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
After a small number of practices joined the Enhancing Oncology Model (EOM) in 2023, CMS has made some changes and opened the model back up for new practices to join.
The $2.49 billion cash purchase will give McKesson about 70% ownership of Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures).
In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.
In our ongoing interview with Jessica K. Paulus, ScD, Ontada, she explains potential drivers behind changing trends in care for lung cancer that may have been influenced by the COVID-19 pandemic.
In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.
“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”
Interview on Ontada research presented at ISPOR 2024.
Interview on Ontada research presented at ISPOR 2024.
Interview on Ontada research presented at ISPOR 2024.
Interview on Ontada research presented at ISPOR 2024.
This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.
